Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to HER2-positive Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance
- Status
- RECRUITING
- Phase
- NA
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
- Status
- RECRUITING
- Phase
- NA
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Status
- RECRUITING
- Phase
- PHASE3
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- NA
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Status
- RECRUITING
- Phase
- PHASE1
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
- Status
- RECRUITING
- Phase
- PHASE2
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab
- Status
- UNKNOWN
- Phase
- N/A
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A